Adjuvant for vaccine immunotherapy of cancer - focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity

Cancer Science

Volumn 106, Issue 12, 2015, Pages 1659-1668

  Seya, Tsukasa ^a   Shime, Hiroaki ^a   Takeda, Yohei ^a   Tatematsu, Megumi ^a   Takashima, Ken ^a   Matsumoto, Misako ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antigen presenting dendritic cell (CD8 + DC, CD141+ DC); BCG CWS; PolyI:C; TICAM 1 pathway; Toll like receptor 2 3

Indexed keywords

ANTIINFECTIVE AGENT; BCG VACCINE; CANCER VACCINE; PATTERN RECOGNITION RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; IMMUNOLOGICAL ADJUVANT;

ANTIGEN PRESENTING CELL; CANCER ADJUVANT THERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CYTOPLASM; DENDRITIC CELL; HUMAN; IMMUNOTHERAPY; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR IMMUNITY; AGONISTS; ANIMAL; IMMUNOLOGY; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 3;

EID: 84983095681     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12824     Document Type: Review

References (85)

1. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-95.
2. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-20.
3. Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 2012; 7: 29-54.
4. Matsumoto M, Azuma M, Seya T. Adjuvant Immunotherapy for cancer: basic research to clinical bench. In: Seya T, ed. Inflammation and Immunity in Cancer. Japan: Springer, 2015; 229-42.
5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
6. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8: 279-89.
7. Ikushima H, Yanai H, Taniguchi T. Innate immune receptor signaling and IRF family transcription factors; good deeds and misdeeds in oncogenesis. In: Seya T, ed. Inflammation and Immunity in Cancer. Japan: Springer, 2015; 85-101.
8. Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol 2015; 33: 257-90.
9. Seya T, Shime H, Matsumoto M. Functional alteration of tumor-infiltrating myeloid cells in RNA adjuvant therapy. In: Yamaguchi Y, ed. Cancer Immunotherapy. Springer, 2015; (in press).
10. Yu P, Lübben W, Slomka H, Gebler J et al. Nucleic acid-sensing Toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumors. Immunity 2012; 37: 867-79.
11. Lee J, Sayed N, Hunter A et al. Activation of innate immunity is required for efficient nuclear reprogramming. Cell 2012; 151: 547-58.
12. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006; 6: 644-58.
13. Aliyari R, Ding SW. RNA-based viral immunity initiated by the Dicer family of host immune receptors. Immunol Rev 2009; 227 (1): 176-88.
14. Leong CR, Matsumoto M, Suzuki T, Oshiumi H, Seya T. Nucleic acid sensors involved in the recognition of hepatitis B virus (HBV) in the liver-specific in vivo transfection mouse models-Pattern recognition receptors and sensors for HBV. Med Sci. 2015; 3: 16-24.
15. Oshiumi H. Links between recognition and degradation of cytoplasmic viral RNA in innate immune response. Rev Med Virol 2015; (in press).
16. Seya T, Azuma M, Matsumoto M. Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer. Expert Opin Ther Targets 2013; 17: 533-44.
17. Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205-9.
18. Maruyama C. Treatment of malignant tumors by an extract from tubercle bacilli (tuberculosis vaccine). Nihon Ika Daigaku Zasshi 1971; 38: 267-76.
19. Azuma I, Ribi EE, Meyer TJ, Zbar B. Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst 1974; 52: 95-101.
20. Uehori J, Matsumoto M, Tsuji S et al. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan. Infect Immun 2003; 71: 4238-49.
21. Ishikawa E, Ishikawa T, Morita YS et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med 2009; 206: 2879-88.
22. Yonekawa A, Saijo S, Hoshino Y et al. Dectin-2 is a direct receptor for mannose-capped lipoarabinomannan of mycobacteria. Immunity 2014; 41: 402-13.
23. Ochiai T, Sato H, Sato H et al. Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative gastric cancer patients. Cancer Res 1983; 43: 3001-7.
24. Yasumoto K, Manabe H, Yanagawa E et al. Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin. Cancer Res 1979; 39: 3262-7.
25. Kodama K, Higashiyama M, Takami K et al. Innate immune therapy with a BCG cell wall skeleton after radical surgery for non-small cell lung cancer: a case control study. Surg Today 2009; 39: 194-200.
26. Azuma I, Seya T. Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol 2001; 1: 1249-59.
27. Tsuji S, Matsumoto M, Takeuchi O et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect Immun 2000; 68: 6883-90.
28. Uehori J, Fukase K, Akazawa T et al. Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation. J Immunol 2005; 174: 7096-103.
29. Girardin SE, Boneca IG, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869-72.
30. Toyonaga K, Miyake Y, Yamasaki S. Characterization of the receptors for mycobacterial cord factor in Guinea pig. PLoS ONE 2014; 9: e88747.
31. Murata M. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci 2008; 99: 1435-40.
32. Levine AS, Sivulich M, Wiernik PH, Levy HB. Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidic acid stabilized with poly-l-Lysine, in carboxy methylcellulose [polyI:CLC], a highly effective interferon inducer. Cancer Res 1979; 39: 1645-50.
33. Galluzzi L, Vacchelli E, Eggermont A et al. Trial Watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1: 699-716.
34. Absher M, Stinebring WR. Endotoxin-like properties of poly I. poly C, an interferon stimulator. Nature 1969; 223: 715.
35. Azuma M, Ebihara T, Oshiumi H, Matsumoto M, Seya T. Cross-priming for antitumor CTL induced by soluble Ag + polyI: C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells. Oncoimmunology 2012; 1: 581-92.
36. Sabbatini P, Tsuji T, Ferran L et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012; 18: 6497-508.
37. Marichal T, Ohata K, Bedoret D et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011; 17: 996-1002.
38. Geissmann F, Prost C, Monnet JP, Dy M, Brousse N, Hermine O. Transforming growth factor β1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J Exp Med 1998; 187: 961-6.
39. Jongbloed SL, Kassianos AJ, McDonald KJ et al. Human CD141+ (BDCA-3)+ dendritic cells (DC) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207: 1247-60.
40. Shortman K, Nail SH. Steady-state and inflammatory dendritic cell development. Nat Rev Immunol 2007; 7: 19-30.
41. Poulin LF, Salio M, Griessinger E et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207: 1261-71.
42. Kadowaki N, Ho S, Antonenko S et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-9.
43. Edwards AD, Diebold SS, Slack EM et al. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 2003; 33: 827-33.
44. Fujimoto K, Karuppuchamy T, Takemura N et al. A new subset of CD103+CD8alpha+ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity. J Immunol 2011; 186: 6287-95.
45. Andoniou CE, van Dommelen SL, Voigt V et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol 2005; 6: 1011-9.
46. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007; 26: 503-17.
47. Finotto S, Glimcher L. T cell directives for transcriptional regulation in asthma. Springer Semin Immunopathol 2004; 25: 281-94.
48. + dendritic cells, which promotes antitumor T cell responses by Poly(I:C). Cancer Res 2015; (in press).
49. Pantel A, Teixeira A, Haddad E, Wood EG, Steinman RM, Longhi MP. Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation. PLoS Biol 2014; 12: e1001759.
50. Zehner M, Marschall AL, Bos E et al. The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8(+) T cells. Immunity 2015; 42: 850-63.
51. Gerner MY, Heltemes-Harris LM, Fife BT, Mescher MF. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol 2013; 191: 1011-5.
52. Yamazaki S, Iyoda T, Tarbell K et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003; 198: 235-47.
53. Miyake T, Kumagai Y, Kato H et al. Poly I:C-induced activation of NK cells by CD8alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways. J Immunol 2009; 183: 2522-8.
54. Tezuka H, Abe Y, Iwata M et al. Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature 2007; 448: 929-33.
55. Atarashi K, Nishimura J, Shima T et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008; 455: 808-12.
56. Akazawa T, Ebihara T, Okuno M et al. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci USA 2007; 104: 252-7.
57. Ebihara T, Azuma M, Oshiumi H et al. Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation. J Exp Med 2010; 207: 2675-87.
58. Kasamatsu J, Azuma M, Oshiumi H et al. INAM plays a critical role in IFN-γ production by NK cells interacting with polyinosinic-polycytidylic acid-stimulated accessory cells. J Immunol 2014; 193: 5199-207.
59. Tatematsu M, Nishikawa F, Seya T, Matsumoto M. Toll-like receptor 3 recognizes incomplete stem structures in single-stranded viral RNA. Nat Commun 2013; 4: 1833.
60. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011; 17: 2619-27.
61. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-68.
62. Matsumoto M, Seya T, Kikkawa S et al. Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int Immunopharmacol 2001; 1: 1559-69.
63. Matsumoto M, Tatematsu M, Nishikawa F et al. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nat Commun 2015; 6: 6280.
64. Conforti R, Ma Y, Morel Y et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res 2010; 70: 490-500.
65. Shen KY, Song YC, Chen IH et al. Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells. J Immunol 2014; 192: 4233-41.
66. Azuma M, Sawahata R, Akao Y et al. The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation. PLoS ONE 2010; 5: e12550.
67. Stack J, Doyle SL, Connolly DJ et al. TRAM is required for TLR2 endosomal signaling to type I IFN induction. J Immunol 2014; 193: 6090-102.
68. Shime H, Matsumoto M, Seya T. The role of innate immune signaling in regulation of tumor-associated myeloid cells. In: Seya T, ed. Inflammation and Immunity in Cancer. Japan: Springer. 2015; 25-48.
69. Schmidt J, Welsch T, Jäger D, Mühlradt PF, Büchler MW, Märten A. Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer 2007; 97: 598-604.
70. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
71. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
72. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-9.
73. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-71.
74. Hernández-Ruiz J, Salaiza-Suazo N, Carrada G et al. CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists. PLoS Negl Trop Dis 2010; 4: e871.
75. Shime H, Matsumoto M, Oshium i H et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA 2012; 109: 2066-71.
76. de Bouteiller O, Merck E, Hasan UA et al. Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem 2005; 280: 38133-45.
77. Sica A, Larghi P, Mancino A et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-55.
78. Shime H, Kojima A, Maruyama A et al. Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models. J Innate Immun 2014; 6: 293-305.
79. Maruyama A, Shime H, Takeda Y, Azuma M, Matsumoto M, Seya T. Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling. Biochem Biophys Res Commun 2015; 457: 445-50.
80. Kim S, Takahashi H, Lin WW et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-6.
81. Salaun B, Zitvogel L, Asselin-Paturel C et al. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res 2011; 71: 1607-14.
82. Takemura R, Takaki H, Okada S et al. PolyI:C-induced, TLR3/RIP3-dependent necroptosis backs up immune effector-mediated tumor elimination in vivo. Cancer Immunol Res 2015; 3: 902-14.
83. Atay S, Godwin AK. Tumor-derived exosomes: a message delivery system for tumor progression. Commun Integr Biol 2014; 7: e28231.
84. Ebihara T, Shingai M, Matsumoto M, Wakita T, Seya T. Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. Hepatology 2008; 48: 48-58.
85. Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol 2015; 33: 445-74.